Wandong Medical (600055): Short-term performance pressure expected to gradually improve by 2026.

The core perspective is that the company's performance in the 25th year faced short-term pressures, primarily due to factors such as the timing of revenue recognition, the impact of centralized procurement, and significant expense investments. In the domestic public hospital market, the number of bids won by the company quadrupled in the 25th year, but there was a certain lag in revenue recognition.

CSC Financial Co., Ltd.Apr 28 15:37

AVIC Securities: Significant AI healthcare collaborations emerge, with application scenarios expanding in depth.

AI is transitioning from a 'technical assistance' role to become the core driving force behind the 'value reconfiguration' and 'efficiency revolution' in the healthcare industry, with its commercial value permeating comprehensively from the research and development end to the clinical end, payment end, and patient end.

Zhitong FinanceApr 27 14:10

Wandong Medical (600055.SH) reported its first-quarter performance, with a net loss attributable to shareholders of 15.93 million yuan.

Wandong Medical (600055.SH) disclosed its first-quarter report for 2026. During the reporting period, the company achieved revenue of 407 million yuan, representing a year-on-year increase of 8.92%. The net profit attributable to shareholders recorded a loss of 15.93 million yuan, turning from profit to loss compared with the same period last year. The non-recurring net profit also turned from profit to loss, amounting to a loss of 18.03 million yuan. The basic earnings per share were -0.023 yuan.

Zhitong FinanceApr 25 00:05

Wandong Medical 2026 First Quarter Report

SZSIApr 25 00:00 · Announcements

Wandong Medical (600055.SH) reported a net loss of 15.934 million yuan in the first quarter.

Gelonghui reported on April 24 that Wandong Medical (600055.SH) released its Q1 2026 earnings report, showing the company achieved revenue of 407 million yuan in the first quarter, representing a year-on-year increase of 8.92%. The net profit attributable to shareholders was -15.934 million yuan, and the non-recurring net profit attributable to shareholders was -18.0339 million yuan.

Gelonghui FinanceApr 24 16:45

Express News | Wandong Medical, a subsidiary of Midea Group, has released the industry's first rare earth suspension DSA-Genesis X5.

BreakingsApr 10 15:13